Kus-Slowinska Marta, Wrzaskowska Monika, Ibragimow Izabela, Czaklosz Piotr Igor, Olejnik Anna, Piotrowska-Kempisty Hanna
Department of Toxicology, Poznan University of Medical Sciences, 30 Dojazd St., 60-631 Poznan, Poland.
Research and Development Department of Ethifarm, Ethifarm Manufacturing Plant, 9 Stefana Zeromskiego St., 60-544 Poznan, Poland.
Pharmaceutics. 2020 Dec 19;12(12):1238. doi: 10.3390/pharmaceutics12121238.
The Biopharmaceutics Classification System (BCS) was conceived to classify drug substances by their in vitro aqueous solubility and permeability properties. The essential activity of naftidrofuryl oxalate (NF) has been described as the inhibition of the serotonin receptors (5-HT), resulting in vasodilation and decreasing blood pressure. Since the early 1980s, NF has been used to treat several venous and cerebral diseases. There is no data available on the BCS classification of NF. However, based on its physical-chemical properties, NF might be considered to belong to the 1st or the 3rd BCS class. The present study aimed to provide data concerning the solubility and permeability of NF through Caco-2 monolayers and propose its preliminary classification into BCS. We showed that NF is a highly soluble and permeable drug substance; thus, it might be suggested to belong to BCS class I. Additionally, a high dissolution rate of the encapsulated NF based on Praxilene 100 mg formulation was revealed. Hence, it might be considered as an immediate-release (IR).
生物药剂学分类系统(BCS)旨在根据药物在体外的水溶性和渗透性对药物进行分类。草酸萘呋胺酯(NF)的主要活性被描述为对5-羟色胺受体(5-HT)的抑制作用,从而导致血管舒张和血压降低。自20世纪80年代初以来,NF已被用于治疗多种静脉和脑部疾病。目前尚无关于NF的BCS分类数据。然而,基于其理化性质,NF可能被认为属于第一类或第三类BCS。本研究旨在提供有关NF透过Caco-2单层细胞的溶解度和渗透性的数据,并对其进行BCS的初步分类。我们发现NF是一种高溶解性和高渗透性的药物物质;因此,可能建议将其归为BCS I类。此外,基于100 mg普拉克索剂型的包封NF显示出高溶解速率。因此,它可能被视为速释制剂(IR)。